| Literature DB >> 34989646 |
Sedat Kalkan1, Süleyman Cagan Efe1, Ali Karagöz1, Gönül Zeren2, Mehmet Fatih Yılmaz2, Barış Şimşek2, Ulaankhuu Batgerel3, Flora Özkalaycı4, İbrahim Halil Tanboğa4,5,6, Vecih Oduncu7, Can Yücel Karabay2, Cevat Kırma1.
Abstract
Several studies have shown that high uric acid (UA) and low serum albumin (SA) values increase the risk of cardiovascular disease and mortality in ST-elevation myocardial infarction (STEMI). We determined whether the uric acid/albumin ratio (UAR) is a predictor of mortality in STEMI patients. All patients who presented at our center with a diagnosis of STEMI and underwent percutaneous intervention from 2015 to 2020 were screened consecutively; 4599 patients were included. A Cox proportional hazards model was used to evaluate UAR, and adjusted predictors obtained from laboratory findings and clinical characteristics contributed to mortality. Also, a regression model was presented with a directed acyclic graph (DAG). The median age of the patients was 58 years (IQR [interquartile range]: 50-67); 3581 patients (77.9%) were male. The incidence of mortality in the entire patient group was 11.9%. Median follow-up duration of all groups was 42 months. Multivariate Cox proportional regression (model-1) analysis showed age (increase 50 to 67 years; HR [hazard ratio]: 1.34, 95% CI 1.18-1.52) and UAR (increase 1.15-1.73; HR: 1.33, 95% CI 1.16-1.52) were associated with mortality. UAR may be a prognostic factor for mortality in STEMI patients and an easily accessible parameter to identify high-risk patients.Entities:
Keywords: ST-elevation myocardial infarction; albumin; mortality; uric acid; uric acid/albumin ratio
Mesh:
Substances:
Year: 2022 PMID: 34989646 DOI: 10.1177/00033197211066362
Source DB: PubMed Journal: Angiology ISSN: 0003-3197 Impact factor: 3.619